Kroos S, Blomberg N, Kwekkeboom J, Hendriks R, Corneth O, Toes R
Eur J Immunol. 2025; 55(1):e202451361.
PMID: 39821328
PMC: 11739663.
DOI: 10.1002/eji.202451361.
Jiang Q, Peng Y, Herling C, Herling M
Cancers (Basel). 2024; 16(21).
PMID: 39518015
PMC: 11545099.
DOI: 10.3390/cancers16213574.
Bhowmick K, von Suskil M, Al-Odat O, Elbezanti W, Jonnalagadda S, Budak-Alpdogan T
Heliyon. 2024; 10(12):e33091.
PMID: 39021902
PMC: 11252793.
DOI: 10.1016/j.heliyon.2024.e33091.
Abdoul-Azize S, Hami R, Riou G, Derambure C, Charbonnier C, Vannier J
Nat Commun. 2024; 15(1):4557.
PMID: 38811530
PMC: 11136999.
DOI: 10.1038/s41467-024-48818-9.
Schmid V, Hobeika E
Front Oncol. 2024; 14:1339620.
PMID: 38469232
PMC: 10926848.
DOI: 10.3389/fonc.2024.1339620.
Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
Zygmunciak P, Robak T, Pula B
Int J Mol Sci. 2024; 25(3).
PMID: 38338868
PMC: 10855898.
DOI: 10.3390/ijms25031589.
Identification of the Axis β-Catenin-BTK in the Dynamic Adhesion of Chronic Lymphocytic Leukemia Cells to Their Microenvironment.
Mihoub I, Rharass T, Ouriemmi S, Oudar A, Aubard L, Gratio V
Int J Mol Sci. 2023; 24(24).
PMID: 38139452
PMC: 10744074.
DOI: 10.3390/ijms242417623.
Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination.
Elkjaer M, Waede M, Kingo C, Damsbo K, Illes Z
Front Immunol. 2023; 14:1264128.
PMID: 38022591
PMC: 10679451.
DOI: 10.3389/fimmu.2023.1264128.
Role and application of chemokine CXCL13 in central nervous system lymphoma.
Li C, Zhang L, Jin Q, Jiang H, Wu C
Ann Hematol. 2023; 103(8):2671-2680.
PMID: 38010409
DOI: 10.1007/s00277-023-05560-4.
The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors.
Sampietro M, Cassina V, Salerno D, Barbaglio F, Buglione E, Marrano C
Hemasphere. 2023; 7(8):e931.
PMID: 37492437
PMC: 10365208.
DOI: 10.1097/HS9.0000000000000931.
Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis.
Shulga O, Chabanova A, Kotsiuba O
Postep Psychiatr Neurol. 2023; 32(1):23-30.
PMID: 37287740
PMC: 10243295.
DOI: 10.5114/ppn.2023.126319.
Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation.
Pelletier J, Balzano M, Destin J, Montersino C, Delahaye M, Marchand T
iScience. 2023; 26(4):106385.
PMID: 37009219
PMC: 10060685.
DOI: 10.1016/j.isci.2023.106385.
Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
Moldovianu A, Stoia R, Vasilica M, Ursuleac I, Badelita S, Tomescu A
Medicina (Kaunas). 2023; 59(2).
PMID: 36837525
PMC: 9959500.
DOI: 10.3390/medicina59020324.
Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies.
Cao X, Jin X, Zhang X, Utsav P, Zhang Y, Guo R
Curr Treat Options Oncol. 2023; 24(3):184-211.
PMID: 36701037
PMC: 9992085.
DOI: 10.1007/s11864-023-01049-4.
Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.
Maitre E, Paillassa J, Troussard X
Front Oncol. 2023; 12:1068981.
PMID: 36620555
PMC: 9815161.
DOI: 10.3389/fonc.2022.1068981.
Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park H, Chae M, Ko J, Kikkawa D, Jang S, Yoon J
PLoS One. 2022; 17(12):e0279060.
PMID: 36521376
PMC: 9754806.
DOI: 10.1371/journal.pone.0279060.
B-cell targeted therapy of pemphigus.
Yamagami J
J Dermatol. 2022; 50(2):124-131.
PMID: 36478455
PMC: 10107866.
DOI: 10.1111/1346-8138.16653.
The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System.
Cao T, Wang Z, Zhu X
J Inflamm Res. 2022; 15:6427-6438.
PMID: 36452053
PMC: 9704002.
DOI: 10.2147/JIR.S389958.
Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors.
Sousa B, de Almeida C, Barahona A, Lopes R, Martins-Logrado A, Cavaco M
ACS Pharmacol Transl Sci. 2022; 5(11):1156-1168.
PMID: 36407952
PMC: 9667546.
DOI: 10.1021/acsptsci.2c00163.
DOCK2 and phosphoinositide-3 kinase δ mediate two complementary signaling pathways for CXCR5-dependent B cell migration.
Wissmann S, Stolp B, Jimenez A, Stein J
Front Immunol. 2022; 13:982383.
PMID: 36341455
PMC: 9627044.
DOI: 10.3389/fimmu.2022.982383.